Race Oncology Logo

About Race Oncology

Race Oncology Limited, a clinical stage global biotechnology company, focuses on cancer care. Its lead product, bisantrene, is a small molecule anthracene chemotherapeutic. The company is developing bisantrene to address the unmet need of patients across multiple oncology indications, exploring anti-cancer plus cardio-protection. It is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the potent inhibitor of FTO (Fat mass and obesity-associated protein). The company is in collaboration with City of Hope, MD Anderson, Sheba City of Health, and UNC School of Medicine. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.